Shin Nippon Biomedical Laboratories, Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.
Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.
- Contract Research, Toxicology Testing-CRO
- Consulting Services
- Drug Delivery
- Other Names / Subsidiaries
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.